Four novel UCP3 gene variants associated with childhood obesity: Effect on fatty acid oxidation and on prevention of triglyceride storage

International Journal of Obesity

Volumn 36, Issue 2, 2012, Pages 207-217

  Musa, C V ^a,b   Mancini, A ^c   Alfieri, A ^a,d   Labruna, G ^a,c   Valerio, G ^d   Franzese, A ^a   Pasanisi, F ^a   Licenziati, M R ^e   Sacchetti, L ^a   Buono, P ^a,c,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c IRCCS SDN   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

childhood obesity; dominant negative; Oil Red O; palmitate oxidation; telmisartan; UCP3 variants

Indexed keywords

LONG CHAIN FATTY ACID; PALMITIC ACID; TELMISARTAN; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 3;

ARTICLE; BIOCHEMISTRY; BODY MASS; CELL LINE; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFANT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WESTERN BLOTTING;

RATTUS;

EID: 84857053594     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.81     Document Type: Article

References (52)

1. Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiol Rev 2004; 84: 277-359. (Pubitemid 38054374)
2. Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A, Cannon B. UCP1: The only protein able to mediate adaptive nonshivering thermogenesis and metabolic inefficiency. Biochim Biophys Acta 2001; 1504: 82-106. (Pubitemid 32179660)
3. Solanes G, Vidal-Puig A, Grujic D, Flier JS, Lowell BB. The human uncoupling protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts. J Biol Chem 1997; 272: 25433-25436. (Pubitemid 27438845)
4. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. UCP3: An uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 1997; 235: 79-82. (Pubitemid 27302688)
5. Hesselink MK, Keizer HA, Borghouts LB, Schaart G, Kornips CF, Slieker LJ et al. Protein expression of UCP3 differs between human type 1, type 2a, and type 2b fibers. FASEB J 2001; 15: 1071-1073.
6. Weigle DS, Selfridge LE, Schwartz MW, Seeley RJ, Cummings DE, Havel PJ et al. Elevated free fatty acids induce uncoupling protein 3 expression in muscle: A potential explanation for the effect of fasting. Diabetes 1998; 47: 298-302. (Pubitemid 28079993)
7. Tsuboyama-Kasaoka N, Tsunoda N, Maruyama K, Takahashi M, Kim H, Ikemoto S et al. Up-regulation of uncoupling protein 3 (UCP3) mRNA by exercise training and down-regulation of UCP3 by denervation in skeletal muscles. Biochem Biophys Res Commun 1998; 247: 498-503. (Pubitemid 28420855)
8. Schrauwen P, Hesselink MK, Vaartjes I, Kornips E, Saris WH, Giacobino JP et al. Effect of acute exercise on uncoupling protein 3 is a fat metabolism-mediated effect. Am J Physiol Endocrinol Metab 2002; 282: E11-E17. (Pubitemid 34654100)
9. Schrauwen P, Hoppeler H, Billeter R, Bakker AH, Pendergast DR. Fiber type dependent upregulation of human skeletal muscle UCP2 and UCP3 mRNA expression by high-fat diet. Int J Obes Relat Metab Disord 2001; 25: 449-456. (Pubitemid 32289635)
10. Boss O, Samec S, Desplanches D, Mayet MH, Seydoux J, Muzzin P et al. Effect of endurance training on mRNA expression of uncoupling proteins 1, 2, and 3 in the rat. FASEB J 1998; 12: 335-339. (Pubitemid 28106781)
11. Schrauwen P, Schaart G, Saris WH, Slieker LJ, Glatz JF, Vidal H et al. The effect of weight reduction on skeletal muscle UCP2 and UCP3 mRNA expression and UCP3 protein content in Type II diabetic subjects. Diabetologia 2000; 43: 1408-1416.
12. Boss O, Muzzin P, Giacobino JP. The uncoupling proteins, a review. Eur J Endocrinol 1998; 139: 1-9. (Pubitemid 28351225)
13. Sugimoto K, Qi NR, KazdováL, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-1009. (Pubitemid 44297575)
14. Sugimoto K, KazdováL, Qi NR, Hyakukoku M, Kren V, SimákováM et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-Activated receptor-gamma dependent pathway. J Hypertens 2008; 26: 1209-1215. (Pubitemid 351670512)
15. Fortunato G, Fattoruso O, De Caterina M, Mancini A, Di Fiore R, Alfieri A et al. RAS and MTHFR gene polymorphisms in a healthy exercise-trained population: Association with the MTHFR (TT) genotype and a lower hemoglobin level. Int J Sports Med 2007; 28: 172-177. (Pubitemid 46392034)
16. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 2002; 246: 1-190.
17. National High Blood Pressure Education ProgramWorking Group on Hypertension Control in Children Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and adolescents: The Third National Health and Nutrition Examination Survey. Pediatrics 1996; 98: 649-658.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
19. Renold A, Koehler CM, Murphy MP. Mitochondrial import of the long and short isoforms of human uncoupling protein 3. FEBS Lett 2000; 465: 135-140. (Pubitemid 30021460)
20. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp-90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275: 3305-3312. (Pubitemid 30083032)
21. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007; 131: 257-270. (Pubitemid 47576138)
22. Narayan SB, Boriack RL, Messmer B, Bennett MJ. Establishing a reference interval for measurement of flux through the mitochondrial fatty acid oxidation pathway in cultured skin fibroblasts. Clin Chem 2005; 51: 644-646. (Pubitemid 40300245)
23. Schrauwen P, Saris WH, Hesselink MK. An alternative function for human uncoupling protein 3: Protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix. FASEB J 2001; 15: 2497-2502. (Pubitemid 33063178)
24. Himms-Hagen J, Harper ME. Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: An hypothesis. Exp Biol Med 2001; 226: 78-84.
25. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, Moore GB et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 2000; 406: 415-418. (Pubitemid 30625561)
26. Costford SR, Chaudhry SN, Salkhordeh M, Harper M. Effects of the presence, absence, and overexpression of uncoupling protein-3 on adiposity and fuel metabolism in congenic mice. Am J Physiol Endocrinol Metab 2006; 290: E1304-E1312. (Pubitemid 43847916)
27. Son C, Hosoda K, Ishihara K, Bevilacqua L, Masuzaki H, Fushiki T et al. Reduction of diet-induced obesity in transgenic mice overexpressing uncoupling protein 3 in skeletal muscle. Diabetologia 2004; 47: 47-54. (Pubitemid 38141939)
28. Bezaire V, Spriet LL, Campbell S, Sabet N, Gerrits M, Bonen A et al. Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 2005; 19: 977-979. (Pubitemid 40827723)
29. Mingrone G, Rosa G, Greco AV, Manco M, Vega N, Hesselink MK et al. Decreased uncoupling protein expression and intramyocytic triglyceride depletion in formerly obese subjects. Obes Res 2003; 11: 632-640. (Pubitemid 41151614)
30. Ravussin E, Lillioja S, Knowler WC, Christin L, Freymond D, Abbott WG et al. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988; 318: 467-472. (Pubitemid 18054292)
31. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C et al. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997; 15: 223-224.
32. Argyropoulos G, Brown AM, Willi SM, Zhu J, He Y, Reitman M et al. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest 1998; 102: 1345-1351. (Pubitemid 28467562)
33. Urhammer SA, Dalgaard LT, Sørensen TI, Tybjaerg-Hansen A, Echwaldm SM, Andersen T et al. Organisation of the coding exons and mutational screening of the uncoupling protein 3 gene in subjects with juvenile-onset obesity. Diabetologia 1998; 41: 241-244. (Pubitemid 28088404)
34. Brown AM, Willi SM, Argyropoulos G, Garvey WT. A novel missense mutation, R70W, in the human uncoupling protein 3 gene in a family with type 2 diabetes. Hum Mutat 1999; 13: 508.
35. Schrauwen P, Xia J, Walder K, Snitker S, Ravussin E. A novel polymorphism in the proximal UCP3 promoter region: Effect on skeletal muscle UCP3 mRNA expression and obesity in male nondiabetic Pima Indians. Int J Obes Relat Metab Disord 1999; 23: 1242-1245. (Pubitemid 30011948)
36. Otabe S, Clement K, Dubois S, Lepretre F, Pelloux V, Leibel R et al. Mutation screening and association studies of the human uncoupling protein 3 gene in normoglycemic and diabetic morbidly obese patients. Diabetes 1999; 48: 206-208. (Pubitemid 29019375)
37. Cassell PG, Saker PJ, Huxtable SJ, Kousta E, Jackson AE, Hattersley AT et al. Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin. Diabetologia 2000; 43: 1558-1564. (Pubitemid 32734864)
38. Herrmann SM, Wang JG, Staessen JA, Kertmen E, Schmidt-Petersen K, Zidek W et al. Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. J Mol Med 2003; 81: 327-332. (Pubitemid 36718330)
39. Halsall DJ, Luan J, Saker P, Huxtable S, Farooqi IS, Keogh J et al. Uncoupling protein 3 genetic variants in human obesity: The c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population. Int J Obes Relat Metab Disord 2001; 25: 472-477. (Pubitemid 32289639)
40. Liu YJ, Liu PY, Long J, Lu Y, Elze L, Recker RR et al. Linkage and association analyses of the UCP3 gene with obesity phenotypes in Caucasian families. Physiol Genomics 2005; 22: 197-203. (Pubitemid 41356353)
41. Alonso A, Marti A, Corbalan MS, Martinez-Gonzalez MA, Forga L, Martinez JA. Association of UCP3 gene-55C/T polymorphism and obesity in a Spanish population. Ann Nutr Metab 2005; 49: 183-188. (Pubitemid 41159835)
42. Dalgaard LT, Hansen T, Urhammer SA, Drivsholm T, Borch-Johnsen K, Pedersen O. The uncoupling protein 3-55 C/T variant is not associated with type II diabetes mellitus in Danish subjects. Diabetologia 2001; 44: 1065-1067. (Pubitemid 32778143)
43. Berentzen T, Dalgaard LT, Petersen L, Pedersen O, Sorensen TI. Interactions between physical activity and variants of the genes encoding uncoupling proteins -2 and -3 in relation to body weight changes during a 10-y follow-up. Int J Obes 2005; 29: 93-99. (Pubitemid 40065470)
44. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 2004; 53: 726-734. (Pubitemid 38270643)
45. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466-8471. (Pubitemid 36842568)
46. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-Activated receptor-gamma. Int J Biochem Cell Biol 2006; 38: 766-781. (Pubitemid 43372054)
47. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-Activated receptor-gamma activity. Circulation 2004; 109: 2054-2057. (Pubitemid 38620211)
48. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desa P, Pravenec M et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 993-1002. (Pubitemid 38579904)
49. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576: 492-497. (Pubitemid 39388651)
50. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebocontrolled 12-month study. Hypertens Res 2004; 27: 457-464. (Pubitemid 39157547)
51. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005; 28: 498. (Pubitemid 40170973)
52. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguch Y, Ozaki N et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757-758. (Pubitemid 40315351)